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Background/aim: It is claimed that aberrant immune response has a more important role than the cytopathic effect of the virus in the
morbidity and mortality of the coronavirus disease 2019 (COVID-19). We aimed to investigate the possible roles of tumor necrosis
factor-like weak inducer of apoptosis (TWEAK)/Fn14 pathway and leukotrienes (LT) in uncontrolled immune response that occurs in
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Materials and methods: This study included 25 asymptomatic patients and 35 patients with lung involvement who were diagnosed with
COVID-19 as well as 22 healthy volunteers. Lung involvement was determined using computed-tomography. Serum TWEAK, LTE4,
and prostaglandin F2α (PGF2α) levels were determined.
Results: Compared with the healthy control group, TWEAK, LTE4, and PGF2α levels were higher in the group of SARS-CoV-2 infection
without lung involvement. In the group of SARS-CoV-2 infection with lung involvement, age, fibrinogen, sedimentation, C-reactive
protein and ferritin, TWEAK, LTE4, and PGF2α levels were higher, and lymphocyte levels were lower compared with the asymptomatic
group.
Conclusions: In the study, TWEAK and LTE4 levels increased in cases with COVID-19. These results support that TWEAK/Fn14
pathway and LT may involved in the pathology of aberrant immune response against SARS-CoV-2. Inhibition of each of these pathways
may be a potential target in the treatment of COVID-19.
Key words: COVID-19, TWEAK, leukotrienes, inflammation, prostaglandin

1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), which emerged in December 2019 and is a new
member of the coronavirus family, infected millions of
people and caused thousands of deaths worldwide. There
is not a vaccine, and deaths continue to occur at the same
pace. Many epidemiological studies conducted so far have
revealed considerable amount of data on the transmission
route and clinical presentation of the disease. Thus,
methods of protection from SARS-CoV-2 and protocols
for identifying possible cases have been established.
It has been noted that the main cause of death
associated with SARS-CoV is a cytokine storm [1].
Although cytopathic effects of the virus are believed to

be noteworthy in the severity of the disease, experience
and clinical results from other coronaviruses, severe
acute respiratory syndrome coronavirus (SARS-CoV-2),
and Middle East respiratory syndrome virus (MERSCoV) indicate that the aberrant host immune response
causes an inflammatory cytokine storm and mortality
[1]. Similar to the inflammatory cytokines in SARS and
MERS, patients with SARS-CoV-2 also have increased
plasma concentrations of inflammatory cytokines, such
as interleukins (IL)-6 and IL-10, tumor necrosis factor-α
(TNFα), granulocyte colony-stimulating factor (G-CSF)
[2]. The effectiveness of the IL-6 inhibitor tocilizumab,
which is used to stop cytokine storm, supports this view
[3].
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TNF-like weak inducer of apoptosis (TWEAK) is a
member of the TNF ligand family and is first synthesized as
a transmembrane protein of 249 amino acids [4]. Although
it was initially described as an apoptosis stimulant [5],
subsequent studies have shown that it is involved in many
inflammatory and immunological processes [6,7].
TWEAK binds to fibroblast growth factor-inducible
14 (Fn14), its only known receptor, [8], and it stimulates
the release of cytokines such as TNFα, IL-1, IL-6, G-CSF,
and interferon-γ monocyte chemoattractant protein 1,
macrophage inflammatory protein 1 alpha, intercellular
adhesion molecule 1, vascular cell adhesion molecule 1
(VCAM-1), and interferon-γ-induced protein 10 (IP-10)
from TWEAK tissues that increase with inflammation
[9-11]. These data show that the TWEAK/Fn14 pathway
makes a considerable contribution to the inflammation
occurring in the tissues, and the excessive or persistent
upregulation of this pathway plays an important role in the
pathogenesis of some pathological inflammatory diseases
such as systemic lupus erythematosus and rheumatoid
arthritis (RA) [12-14].
Leukotrienes (LT) are generated as a result of the
arachidonic acid metabolism and are lipid mediators of
the inflammatory response. LTs are divided into two as dihydroxy acid LT (LTB4) and cysteinyl LTs (CysLTs; LTC4,
LTD4, and LTE4). LTE4, which is one of the CysLTs, is
the form that is more stable and abundant in biological
fluids compared with others. CysLTs is known to play an
important role in inflammatory diseases of the respiratory
tract, such as asthma [15], pulmonary inflammation and
fibrosis [16], and acute respiratory distress syndrome
(ARDS) [17-19].
It is considered that the more morbid and mortal
course of COVID-19 in some individuals is not due to the
cytopathic effect of the virus but rather due to the aberrant
immune response developed by the host against the virus
[3]. In this study, we aimed to investigate the possible
roles of TWEAK/Fn14 pathway and LTs in the immune
response caused by SARS-CoV-2.

2.2. ELISA tests
Peripheral venous blood samples were collected at
presentation. The blood samples were centrifuged at 3000
x g for 10 min and the sera were stored at –80 °C. On the
evaluation day, the sera were melted at room temperature.
When the samples had higher concentrations, they were
diluted and measured in duplicate.
The concentrations of TWEAK (Human Tumour
Necrosis Factor Related Weak Inducer of Apoptosis, Cat.
No. E1820Hu, Bioassay Technology Laboratory, Shangai,
China), LT - E4 (Human Human Leukotriene, Cat. No.
CSB - E05176h, Cusabio Biotech Co Ltd., Wuhan, China),
and Prostaglandin F2α (PGF2α) (Human Prostaglandin
F2α, Cat. No. CSB - E10142h, Cusabio Biotech Co
Ltd., Wuhan, China) in serum were determined using
commercially available Enzyme Linked Immunosorbent
Assay (ELISA) kits. The enzymatic reactions were
quantified in an automatic microplate photometer. The
concentrations of them were determined by comparing
the optic density of the samples to the standard curve. All
assays were conducted according to the instructions of the
manufacturers.

2. Materials and methods

3. Results
Thirty-five patients with COVID-19 with lung involvement,
25 asymptomatic patients without lung involvement, and
22 healthy volunteers, as the control group, were included
in the study. TWEAK (Figure 1A), LTE4 (Figure 1B), and
PGF2α (Figure 1C) levels were significantly higher in the
group of SARS-CoV-2 infection without lung involvement
compared with the healthy control group. In contrast, in
the group of COVID-19 with lung involvement, TWEAK,
LTE4, and PGF2α levels were significantly higher
compared with those without lung involvement and the
healthy control group (for all P < 0.001).

2.1. Patients
This study included patients who presented from March
30 to April 30, 2020, with a clinical presentation leading
to suspicion of SARS-CoV-2 infection and were diagnosed
with SARS-CoV-2 infection using polymerase chain
reaction (PCR) of swab samples.
Demographic, clinical, laboratory, and radiological
data of all patients were recorded. Based on computed
tomography findings, patients with SARS-CoV-2 infection
were divided into two subgroups: those with lung
involvement and those without lung involvement.

2.3. Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS 19.0, Chicago, IL,
USA). Quantitative data were expressed as mean ± standard
deviation (SD). Normal distributions were tested with the
Kolmogorov–Smirnov test with Bonferroni correction.
Parametric data were analyzed using the Student’s t-test
(age, hemoglobin, leukocyte, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), platelet,
fibrinogen, TWEAK, LTE4, PGF2α). Mann–Whitney U
test was performed to compare nonparametric data and
to compare the skewed data (neutrophil, lymphocyte,
C-reactive protein, and ferritin). Bivariate pearson
correlation analysis was used for the linear variables. ROC
analysis was performed for TWEAK, LTE4, and PGF2α,
and ROC curves for them were drawn. P values less than
0.05 were considered as significant.
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Age,
aspartate
aminotransferase,
alanine
aminotransferase, fibrinogen, sedimentation, C - reactive
protein, and ferritin levels were significantly higher
(Table) and lymphocyte levels were significantly lower in
COVID-19 patients with lung involvement compared with
those without lung involvement.
In the study, the age was correlated with hemoglobin (r
= –0.464, P < 0.001), lymphocyte (r = –0.337, P < 0.001),
erythrocyte sedimentation rate (ESR) (r = 0.652, P =
0.002), C - reactive protein (CRP) (r = 0.380, P < 0.001),
and LTE4 (r = 0.378, P = 0.004). LTE4 was correlated with
lymphocyte (r = 0.360, P < 0.006), platelet (r = - 336, p <
0.001), CRP (r = 0.362, P < 0.006), fibrinogen (r = 0.456,
P < 0.001), TWEAK (r = 0.548, P < 0.001), and PGF2 α (r
= 0.644, P < 0.001). PGF2α was correlated with CRP (r =
0.292, P = 0.028) and TWEAK (r = 0.319, P = 0.004).
Receiver Operating Characteristic (ROC) curve
analysis was performed to establish the optimal
discriminatory threshold to identify patients with
COVID-19 from healthy controls. All three markers have
the capability of effectively discriminating patients with
COVID-19 from HCs. The area under the curve (AUC) of
PGF2α, TWEAK, and LTE4 was 0.90 (95% CI 0.810–0.993,
P < 0.001), 0.99 (95% CI 0.974–1.000, P < 0.001), and 0.95
(95% CI 0.886–1.000, P < 0.001), respectively (Figure
2). Cut points calculated according to Youden Index. A
level of 27.45 mg/dL (sensitivity 86%, specificity 91%) for
PGF2α, 240.85 mg/dL (sensitivity 97%, specificity 100%)
for TWEAK, and 13.40 mg/dL (sensitivity 88%, specificity
96%) for LTE4 were found as the optimum cutoff points
for defining COVID-19.
4. Discussions
In this study, the possible role of TWEAK and LTE4 in
SARS-CoV-2 infection, which is considered to cause
morbidity and mortality with aberrant immune response
rather than its cytopathic effect, was investigated. TWEAK
and LTE4 levels were higher in both groups with the disease
compared with the healthy control group. Compared with
asymptomatic SARS-CoV-2 infection cases, COVID-19
patients with lung involvement were older, and their levels
of acute phase reactants and oxidative stress markers
(PGF2α) were higher, which is consistent with a more
severe clinical presentation of infection. Moreover, the
TWEAK level, which has been shown to play an important
role in the pathogenesis of autoimmune diseases, and LTE4
levels that play a crucial role in hypersensitivity reactions
such as asthma, were higher in COVID-19 cases with lung
involvement.
It has been demonstrated that the TWEAK/Fn14
pathway is involved in the pathogenesis of diseases in
which the immune system does not have a protective role
but is destructive against the host itself [12,14]. TWEAK,
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Figure 1. Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) (A), leukotriene (LT) E4 (B), and prostaglandin (PG)
F2α (C) values for all groups. Data are represented as mean ± SD.
Significance was indicated with asterisk and numerical sign as
following ***P < 0.001 versus control and ###P < 0.001, #P < 0.05
versus patients without lung involvement group.
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Table. Demographic and laboratory data of study groups.
Healthy control

Patients without lung
involvement

Patients with
lung involvement

P value

Sex (female / male)

10 / 9 (53%)

9/16 (36%)

13/22 (37%)

0.573

Age (years)

39.5 ± 10.7

41.2 ± 21.3

64.6 ± 12.5

<0.001

Hemoglobin (mg / dL)

13.87 ± 0.75

14.10 ± 1.20

14.3 ± 2.3

0.938

WBC (mm )

7758 ± 719

7749 ± 3833

6682 ± 3980

0.594

AST (U / L)

17.03 ± 3.66

24.90 ± 6.50

38.2 ± 19.2

0.016

ALT (U / L)

15.27 ± 2.29

16.6 ± 7.2

30.5 ± 12.8

<0.001

Neutrophil (mm )

3513 ± 940

4802 ± 3591

4200 ± 2010

0.677

Neutrophil (%)

63.05 ± 7.56

58.5 ± 5.7

68.5 ± 7.4

<0.001

Lymphocyte (mm )

1458 ± 194.75

1964 ± 984

1305 ± 650

0.07

Lymphocyte (%)

27.84 ± 4.01

27.40 ± 11.50

22.8 ± 11.8

0.350

Platelet (10 / mm )

249.42 ± 38.82

219 ± 24.0

210 ± 14.0

0.518

Fibrinogen (mg / dL)

238.68 ± 13.58

316 ± 108.0

565 ± 162.0

< 0.001

CRP (mg / L)

1.42 ± 0.50

13.0 ± 12.8

48 ± 30.5

< 0.001

ESR (mm / h)

3.38 ± 1.01

19.70 ± 20.40

82.7 ± 28.7

< 0.001

Ferritin (ng / mL)

123 ± 52

141 ± 128

408 ± 154

< 0.001

3

3

3

3

3

WBC: White blood cells, AST: Aspartate transaminase, ALT: Alanine transaminase, CRP: C-reactive protein, ESR:
Erythrocyte sedimentation rate

Figure 2. ROC curves of prostaglandin (PG) F2α (AUC: 0.902,
p: 0.001), tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) (AUC: 0.990, P = 0.001), leukotriene (LT) E4 (AUC:
0.952, P = 0.001) in the healthy control versus the COVID-19.

Fn14, and RANKL expressions are higher in serum and
synovial fluid in RA patients compared with patients with
osteoarthritis [20]. In a study by Park et al., it was found
that as serum TWEAK levels increased, RA disease activity

also increased [21]. These results suggested that blocking
the TWEAK-Fn14 pathway could be effective in RA
patients. Wisniacki et al. administered TWEAK-blocking
monoclonal antibody (BIIB023) to patients with RA and
showed that inflammatory cytokines were downregulated,
and they have claimed that TWEAK blockers can be
effective in diseases for which TWEAK expression has
been found to be high [12]. In the present study, we have
shown an increased TWEAK expression in COVID-19,
as seen in autoimmune diseases. This result suggests that
the TWEAK/Fn14 pathway is possibly involved in the
immune response to SARS-CoV-2. Therefore, it suggests
that there is an aberrant immune response in COVID-19,
and antiTWEAK monoclonal antibodies may be an
effective treatment method for COVID-19.
An intensive increase in proinflammatory cytokines has
been reported in severe clinical presentations and deaths
associated with SARS-CoV-2 infection. The resulting
cytokine storm leads to cardiovascular collapse, multiorgan
failure, and rapid death [2,22]. It has been noted that
IL-6 plays the most important role in the pathogenesis of
cytokine storm, which develops secondary to SARS-CoV-2
infection [23]. Therefore, tocilizumab is recommended
in COVID-19 treatment protocols (Turkish Ministry
of Health Guide for COVID-19), and the effectiveness
of tocilizumab therapy has also been demonstrated in
clinical trials [3,23]. Conversely, in experimental studies,
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TWEAK/Fn14 activation increases the secretion of many
proinflammatory cytokines including IL-6 [10], whereas
antiTWEAK antibodies have been shown to decrease
the expression of IL-6 and TNFα in animal models [24].
This indicates that the TWEAK/Fn14 pathway may have
an important role in excessive proinflammatory cytokine
release and development of cytokine storm in SARS-CoV-2
infection.
It is claimed that not only cytokine storm but also
eicosanoid storm has a role in the pathogenesis of severe
disease in COVID-19 [25]. Massive cell death and cellular
debris caused by SARS-CoV-2 stimulate the inflammasome
complex and [26] initiate macrophage-derived eicosanoid
storm [27]. Proinflammatory bioactive lipid mediators
such as prostaglandin and LT fuel local inflammation [28].
Thus, a hyperinflammatory clinical condition without
resorption arises, which is resistant to treatments. In
the present study, high LTE4 and PGF2α levels found in
patients with SARS-CoV-2 infection support the view that
hyperinflammation associated with eicosanoid storm is
involved in the pathogenesis of aggravation of the disease
in COVID-19.
It is claimed that montelukast, a potent cysteinyl
leukotriene receptor antagonist, can be a potential
therapeutic agent in COVID-19 [29]. Montelukast
suppresses leukotriene-mediated inflammatory response
by inhibiting the binding of leukotrienes to the receptor
[30]. The most important cause of COVID-19 related
deaths is ARDS. The pathogenesis of ARDS, manifested by
diffuse alveolar damage caused by intense inflammation,
has not been fully understood. However, it is known that
LTE4 and prostaglandins play an important role [31]. In
ARDS patients, leukotriene levels increased by 20 times,
and even by 150 times in complicated cases of ARDS in
comparison with healthy volunteers [31]. Subsequent
studies have also supported the importance of leukotrienes
in the pathogenesis of ARDS [17]. Moreover, it has been
shown in experimental studies that cysteinyl leukotriene

blockers may have favorable effects in the clinical course
of ARDS [17]. In the present study, the higher LTE4 and
PGF2α levels in COVID-19 patients with lung involvement
compared with the asymptomatic group shows the
importance of LTE4 and PGF2 in lung inflammation and
indicate that montelukast, a leukotriene receptor blocker,
can positively contribute to the treatment of cases with
SARS-CoV-2 infection associated pneumonia and ARDS.
In conclusion, the immune system can sometimes
respond in a hypersensitive manner to infectious agents,
just as it does to allergens. In such cases, rather than the
direct cytopathic effect of the infectious agent, the aberrant
response of the immune system comes to the fore in the
clinical presentation, and the destructive effects occur via
the immune system. In the present study, the expression
of TWEAK/Fn14 pathway and leukotrienes, which have
important roles in aberrant immune response reactions, was
found to have increased in COVID-19. When an aberrant
immune response is triggered in SARS-CoV-2 infection,
the probability of treatment success is significantly reduced,
and the disease rapidly leads to death. Therefore, TWEAK/
Fn14 pathway blockade and cysteinyl receptor blockers
may provide a new hope for the treatment of COVID-19.
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